glucuronic acid has been researched along with rifampin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, Z; Khuller, GK; Sharma, S; Zahoor, A | 1 |
| Ahmad, Z; Khuller, GK; Pandey, R; Sharma, S | 1 |
| Choonara, YE; du Toit, LC; Jarvis, DL; Khan, RA; Kumar, P; Murphy, CS; Ndesendo, VM; Pillay, V | 1 |
| Feng, H; Hu, C; Zhu, C | 1 |
| Cheung, KM; Kong, T; Shum, HC; To, MK; Wang, L; Wu, J; Yeung, KW | 1 |
| Fávere, V; Lacerda, L; Laranjeira, MC; Parize, AL; Stulzer, HK | 1 |
| Garg, T; Goyal, AK; Murthy, RS; Rath, G | 1 |
| Agrawal, V; Joseph, R; Krishnan, LK; Mohanan, PV; Muraleedharan, CV; Sabareeswaran, A; Savlania, A; Shenoy, SJ; Umashankar, PR; Unnikrishnan, M; Viswanathan, S | 1 |
| Casjens, M; Chattopadhyay, N; Frechen, S; Höchel, J; Kanacher, T; Ligges, S; Ploeger, B; Rottmann, A; Schultze-Mosgau, MH; Zimmermann, T | 1 |
1 review(s) available for glucuronic acid and rifampin
| Article | Year |
|---|---|
Development and evaluation of pH-sensitive sodium alginate/chitosan microparticles containing the antituberculosis drug rifampicin.
Topics: Alginates; Antibiotics, Antitubercular; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Drug Carriers; Glucuronic Acid; Hexuronic Acids; Hydrogen-Ion Concentration; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Rifampin; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2014 |
8 other study(ies) available for glucuronic acid and rifampin
| Article | Year |
|---|---|
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
Topics: Aerosols; Alginates; Animals; Antitubercular Agents; Drug Carriers; Drug Evaluation, Preclinical; Female; Glucuronic Acid; Guinea Pigs; Hexuronic Acids; Inhalation; Isoniazid; Liver; Lung; Male; Mycobacterium tuberculosis; Nanostructures; Pyrazinamide; Rifampin; Spleen; Time Factors; Tuberculosis | 2005 |
Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses.
Topics: Alginates; Animals; Antitubercular Agents; Area Under Curve; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Ethambutol; Female; Glucuronic Acid; Hexuronic Acids; Isoniazid; Male; Mice; Nanostructures; Pyrazinamide; Rifampin; Tissue Distribution | 2006 |
Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers.
Topics: Alginates; Calcium Chloride; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Emulsions; Glucuronic Acid; Hexoses; Hexuronic Acids; Humans; Hydrogels; Isoniazid; Lactic Acid; Microscopy, Electron, Scanning; Models, Molecular; Nanoparticles; Organic Chemistry Phenomena; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rifampin; Spectrum Analysis; Thermodynamics; Tuberculosis | 2011 |
Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system.
Topics: Alginates; Animals; Calorimetry, Differential Scanning; Drug Delivery Systems; Gels; Glucuronic Acid; Hexuronic Acids; Lactic Acid; Male; Mice; Mice, Nude; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Rifampin; Surface Properties | 2012 |
Fabrication and characterization of monodisperse PLGA-alginate core-shell microspheres with monodisperse size and homogeneous shells for controlled drug release.
Topics: Alginates; Animals; Capsules; Cell Line; Cell Survival; Crystallization; Delayed-Action Preparations; Diffusion; Gels; Glucuronic Acid; Hexuronic Acids; Lactic Acid; Materials Testing; Mice; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rifampin; Surface Properties | 2013 |
Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
Topics: Administration, Inhalation; Alginates; Animals; Antitubercular Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Compounding; Drug Delivery Systems; Female; Glucuronic Acid; Hexuronic Acids; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Particle Size; Rifampin; Tuberculosis | 2016 |
Preclinical evaluation of hydrogel sealed fluropassivated indigenous vascular prosthesis.
Topics: Alginates; Animals; Aorta, Thoracic; Blood Vessel Prosthesis; Gelatin; Glucuronic Acid; Hexuronic Acids; Humans; Hydrogels; Mice; Polyethylene Terephthalates; Rabbits; Rifampin; Swine; Vascular Remodeling | 2017 |
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.
Topics: Area Under Curve; Bilirubin; Cytochrome P-450 CYP3A; Drug Interactions; Female; Glucuronic Acid; Glucuronosyltransferase; Humans; Middle Aged; Models, Biological; Rifampin; Steroids | 2018 |